iTeos Therapeutics, Inc. (ITOS)
NASDAQ: ITOS · Real-Time Price · USD
5.95
-0.37 (-5.85%)
Mar 31, 2025, 1:17 PM EDT - Market open
iTeos Therapeutics Revenue
In the year 2024, iTeos Therapeutics had annual revenue of $35.00M with 177.89% growth.
Revenue (ttm)
$35.00M
Revenue Growth
+177.89%
P/S Ratio
7.31
Revenue / Employee
$202,312
Employees
173
Market Cap
227.26M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
ITOS News
- 5 days ago - iTeos to Present Preclinical Data on Potential Best-In-Class Anti-TREM2 Antibody, EOS-215, and Novel PTPN1/2 Inhibitor at the American Association for Cancer Research Annual Meeting 2025 - GlobeNewsWire
- 26 days ago - iTeos Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates - GlobeNewsWire
- 4 weeks ago - iTeos Therapeutics: Decimated By Collateral Events, Good Chances Of Success Nevertheless - Seeking Alpha
- 3 months ago - iTeos Therapeutics: A Perhaps Unjustified Decline To End 2024 - Seeking Alpha
- 3 months ago - iTeos Therapeutics Presents Interim A2A-005 Clinical Trial Data, Translational, and Preclinical Data from Inupadenant at ESMO Immuno-Oncology Congress - GlobeNewsWire
- 4 months ago - iTeos to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 4 months ago - iTeos Reports Third Quarter 2024 Financial Results and Provides Business Updates - GlobeNewsWire
- 7 months ago - iTeos Therapeutics, Upstart Holdings And Other Big Stocks Moving Lower In Monday's Pre-Market Session - Benzinga